KDR and neoplasm: It targets the vascular endothelial growth factor receptor‐2 (VEGFR‐2) of tumor cells, which can selectively compete for the ATP receptor of intracellular VEGFR‐2, blocking downstream signal transduction pathway intracellularly thereby inhibiting tumor angiogenesis.